You’ve probably heard the news by now. The massive deal that was supposed to swallow up STAAR Surgical is dead. On January 9, 2026, the proposed merger with Alcon officially bit the dust because shareholders simply weren't having it. If you’ve been watching staar surgical company stock lately, you know the vibe has shifted from "waiting for a buyout" to "what happens now?"
It is a wild time to be an investor in the eye-care space. One day you’re looking at a $30.75 per share cash offer, and the next, you’re staring at a ticker price hovering around $21. The market is basically trying to figure out if this company can actually stand on its own two feet or if the activists who blocked the deal just cost everyone a lot of money.
The Alcon Drama and the Broadwood Power Move
Let’s be real: Broadwood Partners and Neal Bradsher played a high-stakes game of chicken with Alcon, and they won—or lost, depending on who you ask. Broadwood, which owns about 31% of the company, basically led a rebellion. They argued that Alcon's "premium" offer was actually a lowball and that STAAR is worth way more in the long run.
They weren't just talk, either. As of January 15, 2026, Broadwood has already placed three new members on the board: Neal Bradsher, Richard LeBuhn, and Christopher Wang. This isn't a passive investment anymore. This is a complete takeover of the company's direction.
Why the Deal Collapsed
- Shareholder Resistance: Despite the board initially saying yes, the big institutional players didn't see enough value.
- Independence over Exit: The narrative shifted to STAAR being a "standalone winner" in the ICL (Implantable Collamer Lens) market.
- Activists at the Gates: Broadwood wasn't just voting no; they were calling for a total overhaul of leadership.
The stock took a hit immediately after the news broke, dropping from those high 20s back down into the low 21s. It’s painful to watch if you bought in during the merger hype, but for those looking at the fundamentals, this is where the real story begins.
Breaking Down the Financial Mess and the Upside
Honestly, the numbers are a bit of a mixed bag right now. In late 2025, STAAR reported some pretty decent revenue—about $94.7 million for the third quarter. But there's a catch. A huge chunk of that ($25.9 million) came from a single massive shipment to China that had been delayed since 2024. Without that one-time boost, the growth looks a lot more modest.
The company isn't profitable yet on a GAAP basis. Analysts are forecasting a net loss of around $96 million for the full year 2026, though some optimists think they could turn a tiny profit of $0.06 to $0.11 per share if everything goes perfectly. That’s a big "if."
The China Problem
China is the elephant in the room for staar surgical company stock. About 95% of their revenue comes from outside the U.S., and a massive portion of that is tied to Chinese distributors. The problem? Those distributors are currently thinning out their inventory. They aren't buying new lenses as fast because they already have too many on the shelves. Until that "destocking" ends, the revenue numbers are going to look shaky.
Is the EVO ICL Actually Better than LASIK?
This is the core of the bull case. If you're betting on STAAR, you're betting that people will stop wanting to laser their eyeballs and start wanting a removable lens instead.
📖 Related: How Much is Rs in Dollars: What Most People Get Wrong
The EVO ICL is their flagship. Unlike LASIK, which cuts away part of your cornea, the ICL is like a permanent contact lens tucked behind your iris. It’s reversible. That’s a huge selling point for younger Gen Z and Millennial patients who are nervous about permanent surgery.
However, the competition is getting fierce. Carl Zeiss Meditec is crushing it with their SMILE technology, and their revenue in this space jumped over 15% recently. Alcon, the very company that tried to buy STAAR, is now their biggest rival again, pushing their "Wavelight Plus" personalized LASIK.
What the Pros are Saying About the Stock Right Now
Wall Street is currently in a "wait and see" mode. Canaccord Genuity just slashed their price target from $30.75 (the merger price) down to $22. That’s a cold shower for anyone hoping for a quick rebound.
Most analysts are sitting at a Hold rating.
Why?
Because the roadmap is blurry. Stephen Farrell, the CEO, is staying on until the end of January 2026, but after that, it's anyone's guess who will lead the ship. A company without a permanent CEO and a board full of activist investors usually means one thing: volatility.
Practical Moves for the Next Few Months
If you're holding staar surgical company stock or thinking about jumping in, don't expect a smooth ride. The next big date is February 10, 2026, which is when the Q4 2025 earnings are expected to drop. That will be the first real look at how the company is performing without the "merger fog" in the way.
Watch the Inventory Levels: If the earnings report shows that Chinese distributors are starting to buy again, the stock could pop. If they're still sitting on piles of old lenses, expect more downward pressure.
Keep an Eye on the CEO Search: The board needs to find a heavyweight to replace Farrell. If they land someone with a history of scaling medical tech, it would be a massive confidence boost for the market.
Monitor Insider Buying: Broadwood just bought another $600,000 worth of shares at an average price of $22.05 in early January. When the biggest shareholder is buying the dip, they usually see something the rest of the market is missing.
The standalone path for STAAR is risky, but the tech is solid. You’re essentially buying into a turnaround story now, not a merger arbitrage play.
Actionable Next Steps
- Check the Q4 earnings release on February 10, 2026, specifically looking for "Net Sales excluding China" to see if the rest of the world is picking up the slack.
- Monitor the SEC Form 4 filings to see if Neal Bradsher or other board members continue to buy shares at the $20–$21 level.
- Review the cash-to-debt ratio; currently, STAAR has more cash than debt and a current ratio of 5.21, meaning they aren't going bankrupt anytime soon despite the lack of profits.